CClinicalTrials.gg
CompletedNCT05094778Updated Oct 26, 2021

A Single-portal Endoscopic Approach Through Subcutaneous Tunnel for Carpal Tunnel Release

An interventional study of a single-portal palm approach in Carpal Tunnel Syndrome, sponsored by Shenzhen People's Hospital. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-26.

Sponsored by Shenzhen People's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 years 8 months after the study started (first participant enrolled Jan 2012, registered Oct 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Traditional endoscopic release directly accesses the carpal tunnel and thus carries a higher risk of nerve irritability, even nerve injury. Based on our anatomical study, the investigators developed a new endoscopic technique through a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament. The investigators will compared the technique with the standard dual-portal endoscopic technique.

Read the detailed description

Conduct a multi-center, comparison clinical trial according to clinical Trial Reporting Standards (CONSORT). Patients in the single-portal group were treated with a single-portal palm approach that passes superficially to palmar aponeurosis and cut the full transverse carpal ligament. The comparison group were treated with Chow endoscopic technique. In order to assess efficiency of single-portal palm approach, the investigators will compared the technique with the standard dual-portal endoscopic technique. The study was approved by Shenzhen People's Hospital and informed consent was signed.

02

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • Carpal tunnel syndrome
  • carpal tunnel release
  • pain
  • nerve compression syndromes
03

In context

Carpal Tunnel Syndrome

589 studies on the registry are indexed under Carpal Tunnel Syndrome; 139 are open to participants now.

This study's enrollment of 192 is above the median of 60 across 445 interventional studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Shenzhen People's Hospital is the lead sponsor of 62 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A confirmed diagnosis of carpal tunnel syndrome based on Evidence for Surgical Treatment issued by the British Society for Surgery of the Hand
  • Symptoms of carpal tunnel syndrome had lasted>2 months or inadequate responses to the non-surgical treatments≥3 months
  • moderate to severe symptoms.

Exclusion criteria

Exclusion Criteria:

  • mild symptoms or prior injuries to the extremity
  • bilateral wrists involved, a combined nerve compression, gout, diabetes or chronic renal failure.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Other
    single-portal group

    The patients in single-portal group were treated with single-portal palm approach

    Procedure: a single-portal palm approach

Interventions

  • Procedurea single-portal palm approach

    a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.

06

What researchers measure

Primary outcomes

  1. The sensibility of the pulps of thumb, index finger, and middle finger (mm)

    static 2-point discrimination (2PD) test is used for testing the sensibility of the pulps of digits. The range of normal value is 3 mm--5 mm, and higher scores mean a worse outcome

    Time frame: 3 years

  2. Severity of symptoms and functional status

    The Levine Questionnaire is regarded as a valuable assessment of severity of symptoms and functional status in carpal tunnel syndrome. It is self-administered and is in two sections. The symptoms severity scale is 11 questions and evaluates symptoms regarding severity, frequency, time and kind. The functional status scale is eight questions and evaluates how the syndrome affects daily life.Each question had five ordinal response categories ranging from 1 (no symptoms) to 5 (very severe symptoms). Responses to individual items were averaged to yield an overall score for each scale.

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Shi Q, Bobos P, Lalone EA, Warren L, MacDermid JC. Comparison of the Short-Term and Long-Term Effects of Surgery and Nonsurgical Intervention in Treating Carpal Tunnel Syndrome: A Systematic Review and Meta-Analysis. Hand (N Y). 2020 Jan;15(1):13-22. doi: 10.1177/1558944718787892. Epub 2018 Jul 17. PubMed 30015499 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05094778
Lead sponsor
Shenzhen People's Hospital
Collaborators
Hebei Medical University Third Hospital
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Jan 5, 2012
Primary completion
Jun 15, 2021
Completion
Aug 30, 2021
Last update
Oct 26, 2021

Study contacts

Yongqing Zhuang
principal investigator · Shenzhen People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion